Abstract Search

ba0001oc5.2 | Treatment of osteoporosis | ECTS2013

Fracture risk factors during treatment with denosumab

Cummings Steven , Feng Amy , Black Dennis , Wagman Rachel , Austin Matt , Wang Andrea , Walimbe Mona , Wu Lucy , Lui Lily , Vittinghoff Eric

Background: There are no models for estimating risk of fracture in patients taking treatments for osteoporosis. Knowing a patients risk of fracture during treatment may help make future treatment decisions; therefore, the development of on-treatment fracture risk models is needed.Methods: To assess on-treatment fracture risk, the analysis included subjects who received denosumab (DMAb) 60 mg Q6 every 6 months for at least 1 year in either FREEDOM o...

0 shares

ba0001pp387 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Sclerostin associated with vertebral bone marrow fat in older men but not women

Ma Vivian , Li Xiaojuan , Sigurdsson Sigurdur , Eriksdottir Gudny , Hauksdottir Alda , Palermo Lisa , Hue Trisha , Lang Thomas , Harris Tamara , Rosen Clifford , Vittinghoff Eric , Siggeirsdottir Kristin , Sigurdsson Gunnar , Oskarsdottir Diana , Gudnason Vilmundur , Schwartz Ann

Previous studies found a negative correlation between vertebral bone marrow fat (MF) and bone density (BMD). Proposed mechanisms for this include i) a shift in stem cell lineage allocation from osteoblasts towards adipocytes, and ii) an increase in osteoclast-promoting cytokines with greater MF. However, little is known about the relationship between MF and bone markers. To assess these relationships in older adults, we used data from the AGES-Reykjavik cohort. MF was measured...

0 shares

ePoster

Bone Abstracts

Fracture risk factors during treatment with denosumab

Sclerostin associated with vertebral bone marrow fat in older men but not women

BiosciAbstracts